Celltrion stock

068270 · KRX · KRW

₩214,500.00Change from previous close: +0.23%Absolute change: +₩500.00

Close · November 16, 2026

Price history

+18.60% over the period

1 year: from ₩180,857.14 (November 17, 2025) to ₩214,500.00 (November 16, 2026), +18.60%.

Show chart data

Closing prices adjusted for splits: the last close of each month.

DateClose
November 16, 2026₩214,500.00
October 30, 2026₩191,600.00
September 30, 2026₩177,700.00
August 31, 2026₩188,900.00
July 31, 2026₩186,700.00
June 30, 2026₩173,300.00
May 29, 2026₩183,714.28
April 30, 2026₩190,952.38
March 31, 2026₩187,809.53
February 27, 2026₩227,142.86
January 30, 2026₩200,000.00
December 30, 2025₩172,380.95
November 28, 2025₩176,761.91
November 17, 2025₩180,857.14

At a glance

  • The company

    Biopharmaceutical company developing, producing and selling biosimilars for conditions including rheumatoid arthritis, cancer, inflammatory bowel disease and others

  • Latest results

    Quarter to September 30, 2026 · EPS ₩328.52 (estimate ₩1,653.73)

TickerLandia's take on Celltrion

Analysis calculated by TickerLandia from financial statements and prices, with public rules. Not investment advice. How we analyse stocks

Where the price stands

52-wk low₩158,500.00
52-wk high₩239,047.62

−10.27% from the 52-week high

Analysts · 22 analysts

Average target₩278,545.47+29.86% vs. price

Buy 20 · Hold 2 · Sell 0 · Buy

TickerLandia Fingerprint: Celltrion

Compared with similar companies: very high earnings stability.

Financials and price compared with 61 companies in the biotechnology industry, worldwide. Momentum and risk compared with 1,069 Asia-Pacific stocks.

Position in the group from 0 to 100 (100 = highest value): it describes, it does not rate. Tap a row for the metrics. Calculated on November 16, 2026. An indicator calculated by TickerLandia from financial statements and market data. How it is calculated

Valuation

Celltrion is cheaper than in the past and cheaper than similar companies

On the latest fiscal year's earnings (2025), Celltrion's P/E today is 48.3, below the median of its last 10 fiscal years (77.2; between 38.8 and 115.2 from 2016 to 2025). Celltrion's P/E (trailing 12 months): 26.4, −34% against the median of a group of 8 similar companies (40.2).

P/E compared with its history

Compared with 8 similar companies

Celltrion's metrics compared with similar companies
MetricCelltrionPosition in the groupBand
P/E (trailing 12 months)26.4Low
Forward P/E27.1Middle
Operating margin31.6%Middle
ROE9.1%Middle
Debt/equity0.21Middle

P/E at fiscal year end; today on the latest fiscal year's earnings. Grey band: the middle half of the group; tick: the median; dot: Celltrion. All multiples and dividends

TickerLandia analysisHow it is calculated

The financials

The business in numbers

Revenue

₩1.39T

Latest quarter · Q2 2026

Net income

₩370.2B

Latest quarter · Q2 2026

Quarterly net margin

26.6%

Latest quarter · Q2 2026

Numbers and valuation

Full valuation
Market cap
₩49.04T
P/E
26.4
EPS
₩6,840.22
Volume
465.27K
Daily trading
€85.22M
Dividend yield
0.33%
Last ex-dividend on December 29, 2025

How Celltrion is changing

All results
  • Revenue grew 17.6% a year on average over the last 5 years

  • Free cash flow equal to 82% of net income

  • Shares outstanding up 39.1% in 5 years

Returns

Celltrion returns with dividends

₩1,000 invested in Celltrion 5 years ago, on November 16, 2021, would be worth ₩1,159 today with dividends reinvested: +15.87% in total, +2.99% per year. On price alone it would be ₩1,139 (+13.93%).

PeriodCelltrion₩1,000 becomes
1 month+10.57%₩1,106
6 months+19.29%₩1,193
Year to date+24.43%₩1,244
1 year+19.09%₩1,191
3 years+47.83%₩1,478
5 years+15.87%₩1,159
10 years+195.38%₩2,954

From 1 year up with dividends reinvested, before taxes; under a year price only. Calculate your investment

The chart in detail

Celltrion: technical analysis

Celltrion shows no clear trend: the price and its 50- and 200-session averages are not aligned. The price is 34.0% below its all-time closing high (₩325,235.47, December 7, 2020).

Trend
No clear trend
RSI (14 sessions)
68
Between 30 and 70
vs 200-session average
+12.82%

Support and resistance

Price areas where Celltrion has stopped several times in the last year. They describe the chart; they are not forecasts.

  1. No resistance above: the price is near the highs of the year
  2. Last price₩214,500.00
  3. Support₩211,952.38−1.19%4 touches, last on August 12, 2026
  4. Support₩201,113.09−6.24%4 touches, last on October 21, 2026
  5. Support₩189,551.90−11.63%10 touches, last on November 4, 2026

Volatility and risk

Volatility (60 sessions, annualised)
29.9%
Largest fall in the last year
−32.65%

Close of November 16, 2026. Descriptive data calculated on daily prices: it describes the chart and is not investment advice. Beta and volatility describe the last year and can change a lot from one year to the next. How we calculate it

Celltrion: seasonality

Average monthly price change over 22 years

+3.5%Jan+4.5%Feb+2.7%Mar−1.4%Apr+12.1%May+7.8%Jun−0.3%Jul−1.8%Aug+0.0%Sep−1.2%Oct+4.6%Nov+4.8%Dec

Over the last 22 years, the strongest month for Celltrion has been May: +12.11% on average, positive in 11 years out of 21. The weakest has been August: −1.77% on average, positive in 10 years out of 22. November, the current month, has been positive in 12 years out of 21 (+4.55% on average).

Show chart data
MonthAverageMedianPositive years
January+3.54%+1.99%11 of 21
February+4.52%+2.98%13 of 21
March+2.69%+5.03%13 of 21
April−1.41%−0.55%10 of 21
May+12.11%+1.14%11 of 21
June+7.84%0.00%10 of 21
July−0.28%−4.12%8 of 21
August−1.77%−0.41%10 of 22
September+0.03%−3.50%9 of 22
October−1.20%−0.84%10 of 22
November+4.55%+3.24%12 of 21
December+4.82%+2.37%12 of 21

Price change only, dividends excluded. Past seasonality does not predict future moves.

The company

Celltrion and its competitors

Patients in roughly 100 countries receive Celltrion's medicines, and the United States and Europe are among its main sales territories. The Incheon-based group develops, manufactures and sells biosimilars, which are copies of biologic drugs, for autoimmune diseases, cancers, osteoporosis, eye disorders and asthma. Its marketed brands include Remsima, Truxima, Herzuma, Yuflyma, Vegzelma, Omlyclo, Eydenzelt, Steqeyma, Stoboclo, Osenvelt, Avtozma and Zymfentra, along with Regkirona for COVID-19.

Headquarters
Incheon, South Korea
Employees
2,956
Founded
2002
Celltrion and its competitors
CompanyMarket capOperating marginP/E (trailing 12 months)6 months
Celltrion068270$36.68B31.6%26.4+19.29%
Samsung Biologics207940$49.13B45.5%33.4+0.28%
WuXi Biologics (Cayman)2269$24.52B32.4%35.1+38.78%
CSLCSL$65.65B26.8%—+106.74%
Innovent Biologics1801$18.84B7.4%111.5+2.32%
Sichuan Kelun-Biotech Biopharmaceutical6990$13.65B-0.2%—+0.78%

Same industry or related industries, similar size. Compare Celltrion with its competitors · Full profile